Cannabidivarin (CBDV) is a non-psychoactive cannabinoid structurally similar to CBD but with unique therapeutic properties. It is most notably being studied for its anti-epileptic and neurobehavioral benefits, especially in conditions such as autism spectrum disorder (ASD), epilepsy, and Rett syndrome. CBDV works by interacting with non-cannabinoid receptors involved in neurological signaling, including TRP channels and GABA pathways.

 

A groundbreaking study published in The British Journal of Pharmacology demonstrated that CBDV significantly reduced seizure activity and improved neurological function in animal models. Ongoing human trials are evaluating its safety and efficacy in treating pediatric epilepsy and behavioral symptoms related to autism. While still emerging in the marketplace, CBDV holds great promise as a cannabinoid focused on brain health, seizure management, and neurodevelopmental support, without the intoxicating effects associated with THC.